Category: ADCs Pipeline

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the therapeutic features of a chemotherapy / cytotoxic drug. Such conjugates

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADC Therapeutics are engineered therapies comprised of monoclonal antibodies

Antibody Drug Conjugates (ADCs) known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA.  This was followed by the successful

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership will aim at the development of drugs combining ADC Therapeutics’ pyrrolobenzodiazepine-based cytotoxic warheads with Avacta’s Affimer targeting platform. What are the financial terms of the agreement: The detailed

On October 31, 2019, Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1/2 study (NCT04145622) evaluating DS-7300. What is DS-7300: DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC). What is B7-H3: It is a Type I transmembrane protein belonging to the B7 family, which includes immune checkpoint

Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models. The data are being presented at the AACR-NCI-EORTC Molecular Targets

Femtogenix, a UK based biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analog from its Pyridinobenzodiazepine (PDD) ADC payload platform in solid tumor models. The presented data demonstrated that Femtogenix’s reduced potency payload has a favorable